Helius Medical Technologies’ (HSDT) Hold Rating Reiterated at Maxim Group

Helius Medical Technologies (NASDAQ:HSDT)‘s stock had its “hold” rating restated by equities research analysts at Maxim Group in a report released on Wednesday, Marketbeat Ratings reports.

Helius Medical Technologies Stock Performance

Shares of NASDAQ:HSDT opened at $0.55 on Wednesday. The company has a market capitalization of $1.63 million, a PE ratio of -0.04 and a beta of 1.60. The stock has a fifty day moving average of $0.70 and a 200-day moving average of $1.66. Helius Medical Technologies has a one year low of $0.37 and a one year high of $9.50.

Helius Medical Technologies (NASDAQ:HSDT) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.14). Helius Medical Technologies had a negative return on equity of 258.06% and a negative net margin of 1,487.54%. The company had revenue of $0.18 million during the quarter. During the same quarter in the prior year, the company earned ($3.00) earnings per share.

Institutional Investors Weigh In On Helius Medical Technologies

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Armistice Capital LLC bought a new stake in Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned approximately 4.39% of Helius Medical Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 18.63% of the company’s stock.

About Helius Medical Technologies

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.